Clinical Trials Directory

Trials / Conditions / Parkinson Disease Psychosis

Parkinson Disease Psychosis

13 registered clinical trials studyying Parkinson Disease Psychosis — 4 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingEffect of Food and Age on the Pharmacokinetics of LY03017
NCT06793995
Luye Pharma Group Ltd.Phase 1
CompletedBioequivalence Study of Pimavanserin 34 mg Capsule
NCT06450184
Humanis Saglık Anonim SirketiPhase 1
RecruitingA Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418
NCT05995782
1ST Biotherapeutics, Inc.Phase 1
RecruitingClinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psych
NCT05824728
Johns Hopkins UniversityPhase 2
RecruitingCharacterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerati
NCT05357612
Vanderbilt University Medical CenterPhase 4
WithdrawnA Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
NCT05344365
Vanda PharmaceuticalsPhase 2
UnknownPresence Hallucination in Parkinson's Disease
NCT04579887
Olaf BlankeN/A
UnknownHallucinations in Parkinson's Disease
NCT04592965
Olaf BlankeN/A
CompletedOpen-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosi
NCT04292223
ACADIA Pharmaceuticals Inc.Phase 4
CompletedCharacterization and Progression of Minor Phenomena in Parkinson's Disease (PD)
NCT05240339
University of Rochester—
UnknownSRC Inhibition as a Potential Target for Parkinson's Disease Psychosis
NCT03661125
King's College LondonEARLY_Phase 1
TerminatedThe INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study
NCT03152292
ACADIA Pharmaceuticals Inc.—
CompletedA Study to Evaluate the Efficacy, Safety and Tolerability of SEP-363856 in Subjects With Parkinson's Disease P
NCT02969369
Otsuka Pharmaceutical Development & Commercialization, Inc.Phase 2